A recent study in Health Affairs found that when the market entry of generic drugs is delayed due to patent fights and other factors, the price tag for lost savings opportunities approaches $1 billion (2020;39[6]:1011-1017).
Among 69 brand-name drugs studied that were expected to lose patent exclusivity in 2010 to 2016, generic entry occurred before or within three months of the expected date for just 38 products (55%), the investigators found. Market entry for generics was delayed